Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Initiator of Colon Cancer Metastasis Identified

By LabMedica International staff writers
Posted on 29 Sep 2011
A recent study highlighted the role of the BVES (blood vessel epicardial substance) protein in the epithelial-mesenchymal transition (EMT) that occurs when the cells comprising a primary tumor begin to spread and metastasize. More...


The acquisition of a mesenchymal phenotype is a critical step in the metastatic progression of epithelial cancers. Adherens junctions (AJs) are required for suppressing EMT but less is known about the role of tight junctions (TJs) in this process. To elucidate further the factors that drive EMT, investigators at Vanderbilt University (Nashville, TN, USA) examined the function of BVES (also known as POPDC1 and POP1) in relation to the initiation of EMT.

BVES is a highly conserved, transmembrane protein that is involved in cell adhesion, cell motility, and most recently has been shown to play a role in vesicular transport. BVES is found in a wide variety of organisms (from flies to humans) and is a member of the evolutionarily conserved Popdc family of proteins. Although the precise molecular function of BVES is unknown, disruption of this protein results in a wide range of developmental defects and impaired cellular processes.

The investigators reported in the September 12, 2011, online edition of the Journal of Clinical Investigation that they had found that BVES was underexpressed in all stages of human colorectal carcinoma (CRC) and in adenomatous polyps, indicating that its suppression occurred early in transformation. At the genomic level, they found that the BVES promoter was heavily methylated, which silenced its expression. Treating cells that were undergoing EMT with a demethylating agent (the drug decitabine, which is currently used to treat myelodysplastic disorders) restored BVES expression. Renewed BVES expression caused the cells to become more epithelial in nature, and their prometastatic characteristics diminished.

“In cancer, typically the primary tumor does not kill you; it is the metastatic disease that proves lethal," said first author Dr. Christopher Williams, assistant professor of medicine and cancer biology at Vanderbilt University. “So, if targeting BVES could interfere with metastasis; that would be very exciting.”

Related Links:

Vanderbilt University



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.